Skip to main content

Advertisement

Table 2 Pathology of invasive MBCs in the general population from SEER and BRCA2 MBCs and ORs in predicting male BRCA2 mutation carrier status

From: Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

  SEER BRCA2 carriers Unadjusted OR (95 % CI) Adjusted ORa (95 % CI)
  Number Percent Number Percent   
Totalb 6351   326    
Morphology
 Ductal carcinoma 5265 86.2 253 95.1 Reference Reference
 Lobular carcinoma 82 1.5 4 1.5 1.02 (0.37–2.79) 1.00 (0.36–2.74)
 Medullary Carcinoma 16 0.3 2 0.8 2.60 (0.59–11.38) 2.34 (0.52–10.39)
TNM stage
 0–1 1699 34.9 44 29.5 Reference Reference
 2 1990 40.9 70 47.0 1.36 (0.93.–1.99) 1.37 (0.93–2.01)
 3–4 1181 24.2 35 23.5 1.14 (0.73–1.77) 1.11 (0.72–1.73)
Histologic grade
 Grade 1 632 12.9 8 3.5 Reference Reference
 Grade 2 2432 49.7 92 39.8 2.99 (1.44–6.19) 2.98 (1.44–6.19)
 Grade 3 1834 37.4 131 56.7 5.64 (2.75–11.60) 5.53 (2.69–11.39)
Lymph node status
 Negative 2773 58.0 123 50.2 Reference Reference
 Positive 2009 42.0 122 49.8 1.37 (1.05–1.78) 1.28 (0.98–1.67)
ER status
 Negative 229 5.3 8 3.3 Reference Reference
 Positive 4064 94.7 236 96.7 1.66 (0.81–3.41) 1.95 (0.93–4.06)
PR status
 Negative 627 15.0 30 13.2 Reference Reference
 Positive 3562 85.0 198 86.8 1.16 (0.79–1.72) 1.30 (0.88–1.92)
HER2 status
 Negative 627 87.8 126 83.4 Reference Reference
 Positive 87 12.2 25 16.6 1.43 (0.88–2.32) 1.30 (0.79–2.13)
Subtypes
 ER+ and/or PR+, HER2− 608 87.5 118 81.9 Reference Reference
 ER+ and/or PR+, HER2+ 80 11.5 22 15.3 1.42 (0.85–2.36) 1.28 (0.76–2.17)
 ER−, PR−, HER2+ 7 1.0 2 1.4 1.47 (0.30–7.18) 1.09 (0.22–5.45)
 Triple-negative (ER−, PR−, HER2−) 0 0.0 2 1.4 – –
 ER+ and/or PR+, HER2− vs. others      1.54 (0.95–2.49) 1.38 (0.84–2.27)
  1. BRCA2 breast cancer 2, early onset gene, CI confidence interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio, PR progesterone receptor, TNM tumour, node, metastasis
  2. Significant results are indicated by boldface type
  3. aAnalyses adjusted for age at diagnosis and calendar year of diagnosis
  4. bSome data for each pathologic feature are not available
Back to article page